NEW YORK , Nov. 15, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape - The global biosimilars market size is estimated to grow by USD 54.35 billion from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of almost 23.63% during the forecast period. Price advantage of biosimilars over biologics is driving market growth, with a trend towards patients and physician's willingness to switch to biosimilars.
However, market access barriers for biosimilars poses a challenge.Key market players include AbbVie Inc., Amgen Inc.
, Biocon Ltd., Biogen Inc., Boehringer Ingelheim International GmbH, Celltrion Healthcare Co.
Ltd., Dr Reddys Laboratories Ltd., F.
Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Gedeon Richter Plc, Halozyme Therapeutics Inc.
, Intas Pharmaceuticals Ltd., Mabion S.A.
, Novartis AG, Pfizer Inc., Samsung Biologics Co. Ltd.
, Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc..
AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View Free Sample Report PDF Forecast period 2024-2028 Base Year 2023 Historic Data 2018 - 2022 Segment Covered Product Type (Monoclonal antibodies, Insulin, Human growth hormone, and Others), Application (Oncology and hematology, Endocrinology, Immunology, and Nephrology), and Geography (Europe, North America, Asia, and Rest of World (ROW)) Region Covered Europe, North America, Asia, and Rest.